Caitlin E. Mills

TL;DR: The LINCS program focuses on cellular physiology shared among tissues and cell types relevant to an array of diseases, including cancer, heart disease, and neurodegenerative disorders.

TL;DR: Significant inter-patient variability is found in the composition and functional programs of ascites cells, including immunomodulatory fibroblast sub-populations and dichotomous macrophage populations, which contributes to resolving the HSGOC landscape and provides a resource for the development of novel therapeutic approaches.

TL;DR: Five different phenotypic and biochemical assays are used to compare approved inhibitors of cyclin-dependent kinases 4/6-collectively regarded as breakthroughs in the treatment of hormone receptor-positive breast cancer to uncover underappreciated differences in CDK4/6 inhibitor activities with potential importance in treating human patients.

TL;DR: The reproducibility of a prototypical perturbational assay: quantifying the responsiveness of cultured cells to anti-cancer drugs and ways to identify context-sensitive factors, thereby improving both the theory and practice of reproducible cell-based assays are provided.

TL;DR: Treatment with YKL-5-124 resulted in no change to RNA polymerase II C-terminal domain phosphorylation, and selective inhibition of CDK7 may be useful for treatment of cancers marked by E2F misregulation.